Innate immune cells and T CD4 cells profile during hepatitis B among HIV co-infection Beninese


  • Rafiou Sdegbindin Experimental and Clinical Biology Laboratory, National School of Applied Biosciences and Biotechnologies, National University of Science, Technology, Engineering and Mathematics (UNSTIM), Dassa-Zoumé, Benin
  • Gatien Adjimon Gbènakpon Lokossou Research Laboratory in Applied Biology, Polytechnic School of Abomey-Calavi, University of Abomey-Calavi, Cotonou, R. Benin
  • Paulin Kpodji Regional Laboratory of the National Agency for Blood Transfusion, Atlantique Littoral, Health Ministry, Bénin
  • Prisca Gnancadja Regional Laboratory of the National Agency for Blood Transfusion, Atlantique Littoral, Health Ministry, Bénin
  • Banarbé Lafia National Reference Center for Research and Care of People Linving with HIV (NRCRCPL-HIV) of Cotonou Bénin
  • Olga Rosine Quenum Laboratory of Hemorrhagic and Viral Fevers (LFHV) of Cotonou Bénin
  • Maximin Senou Experimental and Clinical Biology Laboratory, National School of Applied Biosciences and Biotechnologies, National University of Science, Technology, Engineering and Mathematics (UNSTIM), Dassa-Zoumé, Benin



Innate immune cells, HIV, HBV, Co-infection, Benin


Background: Worldwide, human immunodeficiency virus (HIV) infection remains a real public health. Hepatitis B virus (HBV) and HIV have the same routes of transmission and shared risk factors and epidemiology similarities. The purpose of this study was to assess the impact of HBV and HIV co-infection on T CD4 cells and innate immune cells.

Methods: A cross-sectional and descriptive study was carried among 260 persons living with HIV (PLHIV) admitted and supported with antiviral tri therapy at the national reference center for research and Care of HIV infected person (NRCRC) of the national hospital and university center in Cotonou, Benin. After PLHIV peripheral blood collection, surface hepatitis B antigens (HBsAg) and HIV serology were tested using ELISA (Enzyme linked immuno sorbent assay). White blood cell count and leukocyte formula were performed using flow cytometry. After staining with anti CD4 antibodies, TCD4+ lymphocytes frequency was determined using flow cytometry. Means were calculated using student T test.

Results: Of the 260 PLHIV, 10.77% (n=28) were co-infected with HBV. Our data has shown a significant decrease of lymphocytes among HIV and HBV co-infected persons and a very significant increase in immune innate cells including eosinophils, polynuclear basophils and monocytes, suggesting an important role of innate immune cells during HIV and HBV coinfection.

Conclusion: HIV and HBV coinfection results in hyperinflammatory response associated with viral clearance. How this hyperinflammatory response is mounted was still unclear. More data are needed for better management of HIV and HBV co-infection.


OMS. Organisation Mondiale de la Santé (OMS) Principaux repères sur le VIH/sida. 2020. Avalable at : Accessed on 17 July, 2020.

Matthews PC, Geretti AM, Goulder PJR., Klenerman P.. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in Sub-Saharan Africa. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2014;61:20-33.

Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS Lond Engl. 2017;31:2035-52.

Dharel N, Sterling RK. Hepatitis B Virus–HIV Coinfection: Forgotten but Not Gone. Hepat. B VIRUS. 2014;10:9.

Ganesan M, Poluektova LY, Kharbanda KK, Osna NA. Human immunodeficiency virus and hepatotropic viruses co-morbidities as the inducers of liver injury progression. World J Gastroenterol. 2019;25:398-410.

Rowley MW, Patel A, Zhou W, Wong M, Seetharam AB. Immune Reconstitution Syndrome with Initiation of Treatment of HBV/HIV Co-infection: Activity Flare associated with E antigen Seroconversion. Ann Hepatol. 2019;18:220-24.

Stabinski L, OʼConnor S, Barnhart M, Kahn RJ, Hamm TE. Prevalence of HIV and hepatitis B virus co-infection in sub-Saharan Africa and the potential impact and program feasibility of hepatitis B surface antigen screening in resource-limited settings. J Acquir Immune Defic Syndr. 1999;68(3):S274-85.

Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao J-M, Zhang B, Shi M, Ding X, Tang Z, Fu Y-X, Wang F-S. Circulating and Liver Resident CD4+CD25+ Regulatory T Cells Actively Influence the Antiviral Immune Response and Disease Progression in Patients with Hepatitis B. J Immunol. 2006;177:739-47.

Li M, Sun X-H, Zhu X-J, Jin S-G, Zeng Z-J, Zhou Z-H et al. HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK, ERK and PI3K/AKT pathways in chronic hepatitis-B-infected patients. Lab Invest. 2012;92:295-304.

Liang X-S, Zhou Y, Li C-Z, Wan M-B. Natural course of chronic hepatitis B is characterized by changing patterns of programmed death type-1 of CD8-positive T cells. World J Gastroenterol. WJG. 2010;16:618-24.

Chen Y, Sun R., Wu X, Cheng M, Wei H, Tian Z. CD4+CD25+ Regulatory T Cells Inhibit Natural Killer Cell Hepatocytotoxicity of Hepatitis B Virus Transgenic Mice via Membrane-Bound TGF-β and OX40. J. Innate Immun. 2016;8:30-42.

Trehanpati N, Vyas AK. Immune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer. Scand J Immunol. 2017;85:175-81.

Sun H-Y, Sheng W-H, Tsai M-S, Lee K-Y, Chang S-Y, Hung C-C. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: A review. World J Gastroenterol. WJG. 2014;20:14598-614.

Yuan F, Zhang W, Mu D, Gong J. Kupffer cells in immune activation and tolerance toward HBV/HCV infection. Adv Clin Exp Med Off Organ Wroclaw Med. Univ. 2017;26:739-45.

Cao H, Zhang R, Zhang W. CTLA‑4 interferes with the HBV‑specific T cell immune response (Review). Int J Mol Med. 2018;42:703-12.

Pappoe F, Hagan CKO, Obiri-Yeboah D, Nsiah P. Sero-prevalence of hepatitis B and C viral infections in Ghanaian HIV positive cohort: a consideration for their health care. BMC Infect. Dis. 2019;19:380.

Chun HM, Mesner O, Thio CL, Bebu I, Macalino G, Agan BK et al. Infectious Disease Clinical Research Program HIV Working Group. HIV outcomes in Hepatitis B virus coinfected individuals on HAART. J. Acquir. Immune Defic. Syndr. 2014;1999(66):197-205.

Thio CL, Smeaton L, Saulynas M, Hwang H, Saravanan S, Saravan S et al. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS Lond Engl. 2013;27:191-201.

Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatol Baltim M. 2009;49:S138-45.

Gürtler LG. Effect of antiretroviral HIV therapy on hepatitis B virus replication and pathogenicity. Intervirology. 2014;57:212-7.

Lozes E, Dougnon V, Bankole H, Houngbegnon P, Anato P, Gahou A et al. Prévalence de l’antigène HBs à l’Hôpital de Zone d’Abomey-Calavi/Sô-Ava au Bénin de 2009 à 2014. Int J Biol Chem Sci. 2017.

Dovonou CA, Amidou SA, Kpangon AA, Traoré YA, Godjedo TPM, Satondji AJ et al. Prevalence of hepatitis B in people infected with HIV in Parakou in Benin] Pan Afr Med J. 2015;20:125.

Mandiwana A, Tshitenge S. Prevalence of human immunodeficiency virus-hepatitis B virus co-infection amongst adult patients in Mahalapye, Ngami, Serowe, Botswana: a descriptive cross-sectional study. South Afr Fam Pract. 2017;59:94-7.

Kye-Duodu G, Nortey P, Malm K, Nyarko KM, Sackey SO, Ofori S et al. Prevalence of hepatitis B virus co-infection among HIV-seropositive persons attending antiretroviral clinics in the Eastern Region of Ghana. Pan Afr Med J. 2016;25.

Ilboudo P. Aspect épidémiologiques, cliniques, paracliniques et évolutives de l’hépatite virale B chez les patients infectés par le VIH à l’hôpital de jour de Bobo-Dioulasso. Thèse, Med, Bobo-Dioulasso. 2013;05.

Attia KA. Prevalence and virological profiles of hepatitis B infection in human immunodeficiency virus patients. World J Hepatol. 2012;4:218.

Ocama P, Seremba E, Apica B, Opio K. Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda. Afr Health Sci. 2015;15:328-33.

Sehonou J, Fiogbe AA, Zannou DM, Bashi J, Houngbe F, Kodjoh N. Coinfection VIH-VHB chez des patients sous traitement antirétroviral au Centre National Hospitalier et Universitaire de Cotonou (République du Bénin). Rev CAMES. 2010;85-9.

Otegbayo JA, Taiwo BO, Akingbola TS, Odaibo GN, Adedapo KS, Penugonda S et al. Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol. 2008;7:152-6.

Kaba D, Diallo MS, Barry R, Diakite M, Diane BF, Keita F et al. Prévalence de l’Antigène HBS chez les Personnes Infectées par le VIH à l’Hôpital de Jour de Donka (Guinée). Health Sci Dis. 2020;21.

Lô G, Sow-Sall A, Diop-Ndiaye H, Mandiouba NCID, Thiam M, Diop F, Ndiaye O et al. Prevalence of hepatitis B markers in Senegalese HIV-1-infected patients: HBV/HIV Coinfection in Senegal. J Med Virol. 2016;88:461-5.

Chambal LM, Gudo ES, Carimo A, Corte Real R, Mabunda N, Maueia C et al. HBV infection in untreated HIV-infected adults in Maputo, Mozambique. PloS One 2017;12:e0181836.

Lujan RA, Vrba SM, Hickman HD. Antiviral Activities of Group I Innate Lymphoid Cells. J Mol Biol. 2022;434:167266.

Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;48:1763-71.

Iser DM, Avihingsanon A, Wisedopas N, Thompson AJ, Boyd A, Matthews GV et al. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS Lond Engl. 2011;25:197-205.

Chang CC, Crane M, Zhou J, Mina M, Post JJ, Cameron BA et al. HIV and co-infections. Immunol Rev. 2013;254:114-42.

Sherman AC, Trehanpati N, Daucher M, Davey RT, Masur H, Sarin SK, Kottilil S, Kohli A. Augmentation of Hepatitis B Virus-Specific Cellular Immunity with Programmed Death Receptor-1/Programmed Death Receptor-L1 Blockade in Hepatitis B Virus and HIV/Hepatitis B Virus Coinfected Patients Treated with Adefovir. AIDS Res. Hum. Retroviruses 2013;29, 665–672.

Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A et al. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet Lond Engl. 2002;360:1921-6.

Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;126:39-44.

Brempelis KJ, Crispe IN. Infiltrating monocytes in liver injury and repair. Clin Transl Immunol. 2016;5:e113.

Beckebaum S, Cicinnati VR, Zhang X, Ferencik S, Frilling A, Grosse-Wilde H et al. Hepatitis B virus-induced defect of monocyte-derived dendritic cells leads to impaired T helper type 1 response in vitro: mechanisms for viral immune escape. Immunology. 2003;109:487-95.

Beckebaum S, Cicinnati VR, Dworacki G, Müller-Berghaus J, Stolz D, Harnaha J et al. Reduction in the Circulating pDC1/pDC2 Ratio and Impaired Function of Ex Vivo-Generated DC1 In Chronic Hepatitis B Infection. Clin Immunol. 2002;104:138-50.

Xing Z. Breach of IL-12 monopoly in the initiation of type 1 immunity to intracellular infections: IL-12 is not required. Cell Mol Biol Noisy Gd Fr. 2001;47:689-94.




How to Cite

Sdegbindin, R., Lokossou, G. A. G., Kpodji, P., Gnancadja, P., Lafia, B., Quenum, O. R., & Senou, M. (2022). Innate immune cells and T CD4 cells profile during hepatitis B among HIV co-infection Beninese. International Journal of Research in Medical Sciences, 10(12), 2737–2743.



Original Research Articles